To estimate the effects of UP269-6, a nonpeptide hypertrophies, tubular atrophy, and percentage of sclerotic glomeruli: 5% and 7%, respectively ) . angiotensin II receptor antagonist, and captopril, a Finally, a low dose of UP269-6 ( 1 mg / kg / day ) , converting enzyme inhibitor, on the progression which induced an intermediate level of blood of nephropathy, 77 uninephrectomized diabetic pressure between control and the other treated rats were maintained for 8 months with plasma groups, produced an equivalent degree of glucose levels from 300 to 500 mg / dL. Systemic nephroprotection. Our data demonstrate the and renal parameters were periodically measured, efficacy of this new angiotensin II receptor and, at the time of death, a histological evaluation antagonist on the progression of diabetic renal of renal damage was performed. Control rats (no damage. These results also reinforce the role additional treatment but insulin) showed attributed to angiotensin II in the development of increased blood pressure and urinary albumin renal derangement in this model, as UP269-6 is levels, together with prominent alterations in the devoid of agonistic effect on the kinin system. kidney ( renal and glomerular hypertrophies, ᭧ 1997 American Journal of Hypertension, Ltd. Am tubular atrophy, and 19% of sclerotic glomeruli ) . J Hypertens 1997; 10:275 -281 Captopril ( 50 mg / kg / day ) and UP269-6 ( 10 mg / kg / day ) reduced blood pressure and albumin KEY WORDS: Captopril, angiotensin II receptor, excretion levels, and improved histological renal UP269-6, Wistar rat, blood pressure, renal preservation ( lower renal and glomerular derangement, diabetes mellitus.
I
factor for the progression of diabetic renal injury, as diverse antihypertensive therapies have demonstrated their ability to reduce the decline in renal function associated with established diabetic renal disnsulin-dependent diabetes mellitus ( IDDM ) is a leading cause of the development of end-stage renal failure. 1, 2 The presence of arterial hypertension has been shown to be a concomitant risk ease. 3, 4 However, several antihypertensive regimens have failed to prevent renal damage, even when a comparable level of blood pressure reduction was tion to systemic effects that contribute to elevations a dose that matched the antihypertensive effect of captopril. Finally, a fourth group (n Å 20 ) was given a in blood pressure, AII produces specific actions within the kidney that could enhance the severity of the le-single dose of 1 mg/ kg BW/ day of UP269-6 in order to obtain a lower decrease of blood pressure in the sions. So, together with its well-known efferent vasoconstriction, 9 AII modulates mesangial cell contractil-animals ( UPL ). Treatments other than insulin were administered by a gastric tube. The rats were kept under ity and macromolecular uptake, 10 glomerular permeability to proteins, 11 tubular sodium reabsorption, 12 these conditions for 8 months, and then the animals were killed in order to assess the diabetic renal damage. and vasa recta blood flow. 13 Therapeutical regimens that modulate AII production, bioavailability, or ac-Analytical Periodical determinations of BW, BG, tivity could have renal protective effects through mean blood pressure (MBP ) by tail-cuff method (Letmodification of these renal factors. The recent devel-ica, Barcelona, Spain ), and plasma creatinine by a reopment of new antihypertensive drugs, such as the flectometer device ( Reflotron, Boehringer Mannheim, nonpeptide antagonists of the AII receptor, allows us Mannheim, Germany) were performed in every animal to assess the contribution of the inhibition of AII bio-to estimate the evolution of systemic parameters. Every activity to the more positive outcome of CEIs in the 8 weeks, all the animals were housed in metabolic retardation of renal damage progression. Preliminary cages, with free access to food and water, to collect 24-studies have reported a renal preserving effect of h urine for determining urinary creatinine and urinary these drugs in Sprague Dawley-diabetic rats, 14 dia-albumin excretion (U alb V). The latter was determined betic spontaneously hypertensive rats, 15 as well as in by a radioimmunodiffusion commercial kit specific for models of renal mass ablation. 16, 17 rat albumin (The Binding Site, Birmingham, England ). UP269-6 ( UP ) is a new orally active nonpeptide an-At the time of death, the creatinine clearance ( CrCl ) giotensin II receptor ( AT 1 ) antagonist, with no agonis-was calculated from plasma and urine creatinine valtic properties on AII and the kinin system. 18 In the ues, which were measured on the same day. In addipresent study we have compared the effects of chronic tion, glycosylated hemoglobin (HbA 1c ) levels were detreatment with this drug and with captopril ( a CEI ) termined. on the progression of diabetic nephropathy in uni-Light Microscopy Remnant kidneys from all the rats nephrectomized streptozotocin-diabetic rats. Finally, were removed, weighed, and processed for light miwe decided to investigate the effects of a low dose of croscopy. Samples from every kidney were fixed by UP in order to evaluate the repercussions of different immersion in formaldehyde and embedded in paraffin. levels of systemic blood pressure control on the sever-Sections were stained with hematoxylin-eosin, periodic ity of the renal damage.
acid-Schiff (PAS) , and Masson trichrome. The presence of focal or diffuse glomerulosclerotic lesions was deter-METHODS mined by scoring at least 75 superficial and midcortical Animals The left kidneys of 77 age-matched Wistar glomeruli in two coronal sections. Glomerular volume rats with initial body weights (BW ) ranging from 300 estimation was performed by using an image analyzer to 350 g were removed under pentobarbital anesthesia. (Microm, Barcelona, Spain) , and values were obtained This maneuver was performed to enhance and hasten by measuring the same glomeruli used to assess histothe severity of diabetic glomerular lesions. 19, 20 Three logical damage. Maximum and minimum glomerular weeks later, the animals were made diabetic by a single diameters between the internal edges of Bowman's capintravenous injection of 70 mg/ kg BW streptozotocin sule were measured and the mean value of both was ( Sigma Chemical Co., St. Louis, MO ) and 2 days later, considered to be the diameter of each glomerulus. From successful induction of diabetes mellitus was confirmed this value, individual volumes were calculated for each by tail blood glucose (BG ) measurement with a re-glomerulus from the formula 4 / 3pr 3 . Tubular lesions flectance meter ( Miles Ames Division, Miles Labora-were evaluated semiquantitatively by the degree of tutories Inc., Elkhart, IN ). Throughout the experiment the bular atrophy as: none ( 0 ), slight ( / ), moderate ( / rats were fed a standard pellet laboratory chow and /) , and intense ( / / /) . allowed free access to water. Every animal received a Statistical Analysis A Wilcoxon's signed rank test for daily injection of ultralente insulin, individually adpaired comparisons was used to analyze differences justed to maintain hyperglycemia ( BG; 300 to 500 mg/ within the groups. Differences between the groups dL ) , which was monitored twice a week. The first were tested by analysis of variance for multiple groups. group ( n Å 17) received no treatment other than insulin P õ .05 was considered significant. In the text, data are ( Control). A second group (n Å 20) was additionally presented as mean { SD. treated with a single dose of 50 mg/ kg BW/ day capto-RESULTS pril ( Capto) . A third group (n Å 20) received a single dose of 10 mg/ kg BW / day of UP269-6 ( UPH). This Clinical and Biochemical Parameters ( Table 1 ) The evolution of blood glucose levels and BW were parallel dose was determined during preliminary studies to be for the four groups during the 8 month follow-up with-dence in the treated groups. In addition, the percentage of sclerotic glomeruli ( Figure 3 ) was significantly deout significant differences among them. The insulin supplementation required to maintain these compara-creased in the treated groups ( P õ .01 v Control) without differences between them. ble BG values was also fairly similar for the four groups. This equivalent metabolic situation was confirmed by DISCUSSION the similar HbA 1c levels shown by the four groups at
In the present study we have tested the effects of capthe time of death. A significant increase in MBP was topril and two different doses of UP269-6, an AIIobserved in the four groups (P õ .05 v week ) , although receptor antagonist, on the progression of experimenthe three treated groups showed significantly lower levtal diabetic nephropathy. We found that captopril exels throughout the follow-up ( P õ .05 v Control ). The hibited nephroprotective actions that included the low dose of UP induced an intermediate level of blood diminution of renal and glomerular hypertrophies, as pressure between the Control and the Capto and the well as a reduction in the renal damage ( percentage UPH groups. The diabetic condition was associated of sclerotic glomeruli and tubulointerstitial lesions) , with an elevation in 24-h urine and Na / excretion in when compared with kidneys from the Control group. the four groups without differences among them durIn addition, CEI treatment induced a decrease in mean ing the study. Urinary albumin excretion ( Figure 1 ) arterial pressure and urinary albumin excretion. Anincreased significantly ( P õ .05 v week 0 ) during the giotensin II receptor blockade, achieved with the high follow-up, although the three therapies evoked a comdose of UP, together with an equivalent reduction in parable reduction in this parameter (P õ .05 v Control) .
blood pressure levels, produced a similar degree of Finally, no difference in the creatinine clearance values preserving activity on the renal structure and function were observed between the groups. as those obtained with captopril. Finally, a comparable level of renal function and architectural preservaMacroscopical and Histological Findings ( Table 2, Figure 2 ) The remaining kidneys obtained from the tion was achieved with a lower dose of UP, although this positive outcome was associated with an intermeanimals at the time of death showed a significant enlargement when compared with the contralateral one diate level of blood pressure between those of the Control and the UPH groups. previously removed (P õ .01) in all the groups. However, all the treatments exerted a diminution in the renal Renal injury is one of the most common features associated with experimental and human diabetes hypertrophy associated with the model ( P õ .05 v Control ). This fact was confirmed by the lower glomerular mellitus. Impaired renal functionality is usually related to hemodynamic and structural alterations hypertrophy observed in the three treated groups ( P õ .05 v Control). A moderate degree of tubular atrophy within the kidney that occur during the progression of the disease. The key mechanism responsible for this and metaplasia was present in the Control group, while these alterations were absent or exhibited a slight inci-derangement is still a matter of speculation, although sustained hyperglycemia and hypertension are recog-tools for estimating the specific contribution of AII to the progression of renal functionality loss. In our nized risk factors that accelerate the progression rate of diabetic renal disease. However, not all antihyper-model, UP induced nephroprotective actions comparable to those achieved with captopril in blood prestensive therapies have shown similar efficacies in retarding this progression, despite the comparable re-sure and glucose-matched conditions. Our data are in agreement with previously published results which ductions of blood pressure levels. 3 -5,21 In this respect, CEIs have demonstrated their ability to slow the de-reported nephroprotective actions of AII receptor antagonist therapies in diabetic rats. 14, 15 The low dose of cline in renal functionality associated with this pathology 7 -9,22 with a diminution of urinary albumin excre-UP269-6 attenuated the progression of diabetic nephropathy in a similar manner to the UPH and Capto tion and amelioration of size-selective properties of the glomerular barrier. 16, 17 Nevertheless, this group of groups, as reflected by comparable levels of albumin excretion, renal and glomerular hypertrophies, and drugs exerts actions other than the direct blockade of the pressor effects of AII. Some extent of the positive the incidence of renal lesions. This positive outcome was not associated with equivalent reductions in outcome obtained with CEIs, such as reduction in protein excretion, has been attributed to the potentiation blood pressure levels. The present result indicates that, although important, blood pressure control is of the bradykinin system 23,24 exerted by these drugs. The relative role played by these or even other mecha-not the only mechanism responsible for diabetic renal injury. In agreement with this statement, it has been nisms in the prevention of renal diabetic injury is still controversial.
previously reported that therapies not affecting systemic blood pressure levels induced nephroprotective Nonpeptide AII receptor (AT 1 ) antagonists, in addition to their therapeutical application, can be useful actions in diabetic models.
25 -28 Indeed, thromboxanes have been implicated in the progression of renal in-sure, which is considered a fundamental factor in the pathogenesis of diabetic renal damage by its preferenjury, as their inhibitors are able to decrease urinary albumin excretion.
25,26 Furthermore, our group has tial vasoconstrictor effect in the efferent arterioles. This early alteration can be enhanced and perpetuated documented that chronic treatment with cicaprost, a PGI 2 analog, not only reduced urinary albumin, but by the trophic effects of AII in the glomerular mesangium and in the renal vasculature. 10 In this regard, also reduced the incidence of glomerular sclerosis and renal and glomerular hypertrophies in the absence of UP269-6 may reduce this intraglomerular pressure, as do other AII receptor antagonists, 30 thus preventing blood pressure control.
27,28 Finally, reductions in blood pressure levels with losartan did not evoke glo-glomerular size-selective functionality, 14 which will further contribute to nephroprotection. The present merular protection in a different model of type II diabetes, 29 reinforcing the statement that in some settings rat model has been reported to involve an overexpression of the renal tissue renin-angiotensin system, the extent of diabetic renal injury can be dissociated from the level of blood pressure.
with specific glomerular and vascular locations. 30 This evidence potentially explains the beneficial response The renal preserving effect induced by both doses of UP seems to support the fundamental and direct to both captopril and UP achieved in our study, as both drugs induce a blockade of AII generation or implication of AII in the pathogenesis of kidney derangement, as this group of drugs does not potentiate action.
All these data indicate that the progression of diathe bradykinin system as do the CEIs. Angiotensin II contributes to the elevation of intraglomerular pres-betic nephropathy is a multifactorial process in which to the relative contribution of each of these systems to the diabetic renal derangement. 11. Remuzzi A, Puntorieri S, Battaglia C, et al: Angiotensin
